Therapeutic potential of pteridine derivatives: A comprehensive review

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B

(2018) Harry L.A. Janssen et al.   JOURNAL OF HEPATOLOGY

Dendritic Cell–Based Cancer Vaccines

(2018) Patricia M. Santos et al.   JOURNAL OF IMMUNOLOGY

ProNGF, but Not NGF, Switches from Neurotrophic to Apoptotic Activity in Response to Reductions in TrkA Receptor Levels

(2017) Maria Ioannou et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use

(2017) Owen A. O’Connor et al.   LEUKEMIA & LYMPHOMA

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

(2017) Mark M. Awad et al.   LUNG CANCER

Exploring the catalytic mechanism of dihydropteroate synthase: elucidating the differences between the substrate and inhibitor

(2017) Warot Chotpatiwetchkul et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation

(2017) Yiming Xu et al.   Nature Communications

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia

(2017) Yoshiya Adachi et al.   Oncotarget

FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway

(2017) Keigo Okada et al.   Oncotarget

In silico Analyses of Subtype Specific HIV-1 Tat-TAR RNA Interaction Reveals the Structural Determinants for Viral Activity

(2017) Larance Ronsard et al.   Frontiers in Microbiology

Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics

(2017) Ping Li et al.   Frontiers in Pharmacology

An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC)

(2017) H. S. Pandha et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)

(2017) P. M. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K

(2017) Simon Law et al.   PLoS One

Characterizing nerve growth factor–p75NTR interactions and small molecule inhibition using surface plasmon resonance spectroscopy

(2016) Kristen S.A. Sheffield et al.   ANALYTICAL BIOCHEMISTRY

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells

(2016) Rujuta A. Bam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy

(2016) Kakoli Mukherjee et al.   BIOCHEMICAL PHARMACOLOGY

Pterin–sulfa conjugates as dihydropteroate synthase inhibitors and antibacterial agents

(2016) Ying Zhao et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pterin-7-carboxamides as a new class of aldose reductase inhibitors

(2016) Ryota Saito et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia

(2016) Elena Ceccacci et al.   BRITISH JOURNAL OF CANCER

Synthesis, Anti-inflammatory and Antibacterial Activities of Novel Pyrazolo[4,3-g]pteridines

(2016) Shawkat Ahmed Abdel-Mohsen et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET

(2016) Luke W. Koblan et al.   ChemMedChem

Monocarboxylate Transporters: Therapeutic Targets and Prognostic Factors in Disease

(2016) RS Jones et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Molybdenum cofactor and human disease

(2016) Guenter Schwarz   CURRENT OPINION IN CHEMICAL BIOLOGY

The ribosomal S6 kinase inhibitor BI-D1870 ameliorated experimental autoimmune encephalomyelitis in mice

(2016) Ichiro Takada et al.   IMMUNOBIOLOGY

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study

(2016) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthesis and Biological Evaluation of New Dipyridylpteridines, Lumazines, and Related Analogues

(2016) Zina A. A. Abbas et al.   JOURNAL OF HETEROCYCLIC CHEMISTRY

Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants

(2016) Deheng Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation

(2016) Yongjia Hao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

(2016) J. Van den Bossche et al.   MEDICINAL RESEARCH REVIEWS

Mechanism of action of methotrexate in rheumatoid arthritis and the search for biomarkers

(2016) Philip M. Brown et al.   Nature Reviews Rheumatology

Pharmacological opportunities to control inflammatory diseases through inhibition of the leukocyte recruitment

(2016) Raphael S. Peres et al.   PHARMACOLOGICAL RESEARCH

PI3K signalling in inflammation

(2015) P.T. Hawkins et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner

(2015) Martín Roffé et al.   CELLULAR SIGNALLING

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer

(2015) Peter M. Ellis et al.   Clinical Lung Cancer

Phase I/IIa trial of volasertib combined with decitabine in patients with acute myeloid leukemia (AML) ineligible for intensive therapy

(2015) Jorge E. Cortes et al.   Clinical Lymphoma Myeloma & Leukemia

Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease

(2015) Daphne Robakis et al.   CNS DRUGS

Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids

(2015) Quaovi H. Sodji et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Pteridine-2,4-diamine derivatives as radical scavengers and inhibitors of lipoxygenase that can possess anti-inflammatory properties

(2015) Eleni Pontiki et al.   Future Medicinal Chemistry

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

(2015) Edward J. Gane et al.   JOURNAL OF HEPATOLOGY

Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase

(2015) Jeroen T Buijs et al.   JOURNAL OF PATHOLOGY

Mechanism of pyranopterin ring formation in molybdenum cofactor biosynthesis

(2015) Bradley M. Hover et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BRD4 Structure–Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536

(2015) Lijia Chen et al.   ACS Medicinal Chemistry Letters

Ricin Trafficking in Cells

(2015) Robert Spooner et al.   Toxins

Folate metabolic pathways inLeishmania

(2015) Tim J. Vickers et al.   Essays in Biochemistry

Extensive Identification of Bacterial Riboflavin Transporters and Their Distribution across Bacterial Species

(2015) Ana Gutiérrez-Preciado et al.   PLoS One

Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels

(2015) Jörg Haupenthal et al.   NEOPLASIA

Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C

(2014) Eric Lawitz et al.   ANTIVIRAL THERAPY

Fragment based search for small molecule inhibitors of HIV-1 Tat-TAR

(2014) Mirco Zeiger et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

Silver(I)/6-hydroxyiminolumazine compounds differently modify renin–angiotensin system-regulating aminopeptidases A and N in human neuroblastoma and glioma cells

(2014) María Jesús Ramírez-Expósito et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Synthesis and Structure–Activity Relationships of Pteridine Dione and Trione Monocarboxylate Transporter 1 Inhibitors

(2014) Hui Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

(2014) B T Gjertsen et al.   LEUKEMIA

Targeting bromodomains: epigenetic readers of lysine acetylation

(2014) Panagis Filippakopoulos et al.   NATURE REVIEWS DRUG DISCOVERY

Tetrahydrobiopterin in Cardiovascular Health and Disease

(2013) Jennifer K. Bendall et al.   ANTIOXIDANTS & REDOX SIGNALING

Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors

(2013) Simeon Bowers et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870

(2013) Alexander J. Edgar et al.   BIOSCIENCE REPORTS

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

(2013) Walter M. Stadler et al.   CANCER

Antitumor effects of BI-D1870 on human oral squamous cell carcinoma

(2013) Chang-Fang Chiu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis

(2013) Samira Sadat Abolmaali et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway

(2013) Xiaojing Meng et al.   CANCER LETTERS

2,4-Diamino-6,7-dimethylpteridine as a fluorescent ligand for binding and sensing an orphan cytosine in RNA duplexes

(2013) Yusuke Sato et al.   CHEMICAL COMMUNICATIONS

Selective and Brain-Permeable Polo-like Kinase-2 (Plk-2) Inhibitors That Reduce α-Synuclein Phosphorylation in Rat Brain

(2013) Danielle L. Aubele et al.   ChemMedChem

Pralatrexate Pharmacology and Clinical Development

(2013) E. Marchi et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Targeting TGF-β signaling in cancer

(2013) Lior H Katz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The lumazine synthase/riboflavin synthase complex: shapes and functions of a highly variable enzyme system

(2013) Rudolf Ladenstein et al.   FEBS Journal

GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees

(2013) Robert E. Lanford et al.   GASTROENTEROLOGY

The diversity-oriented synthesis of pteridines-achievements and potential for development

(2013) Colin J. Suckling   IUBMB LIFE

Bacterial Division Proteins FtsZ and ZipA Induce Vesicle Shrinkage and Cell Membrane Invagination

(2013) Elisa J. Cabré et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Synthesis of Cyclic Pyranopterin Monophosphate, a Biosynthetic Intermediate in the Molybdenum Cofactor Pathway

(2013) Keith Clinch et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant

(2013) Wei Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification and Optimization of Pteridinone Toll-like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis

(2013) Paul A. Roethle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors

(2013) Qibin Su et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phosphoinositide 3-kinase δ/γ inhibition does not prevent concanavalin A-induced hepatitis

(2013) YUANYUAN LIU et al.   Molecular Medicine Reports

Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma

(2013) Mary Rose Pambid et al.   PEDIATRIC BLOOD & CANCER

The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1

(2013) D Neise et al.   Cell Death & Disease

Bisubstrate analog inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: New lead exhibits a distinct binding mode

(2012) Genbin Shi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Synthesis and structure–activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists

(2012) Carolyn D. Dzierba et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

(2012) K Mross et al.   BRITISH JOURNAL OF CANCER

Gold(I) Complexes Incorporating Emissive Mercapto-Pteridine Ligands: Syntheses, X-ray Structure, Luminescence and Preliminary Cytotoxic Evaluation

(2012) Lucy A. Mullice et al.   EUROPEAN JOURNAL OF INORGANIC CHEMISTRY

Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?

(2012) Galina Tsykunova et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Peptide-Conjugated Pterins as Inhibitors of Ricin Toxin A

(2012) Ryota Saito et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure-Based Selectivity Optimization of Piperidine–Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors

(2012) Paola Corona et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

(2012) Julie M. Vose et al.   LEUKEMIA & LYMPHOMA

RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma

(2012) Y. Shimura et al.   MOLECULAR CANCER THERAPEUTICS

Favorable Outcome in a Newborn With Molybdenum Cofactor Type A Deficiency Treated With cPMP

(2012) M. M. Hitzert et al.   PEDIATRICS

Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: New design with improved properties

(2011) Genbin Shi et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Metabolic profiling of pteridines for determination of potential biomarkers in cancer diseases

(2011) Piotr Kośliński et al.   ELECTROPHORESIS

Nitric oxide synthases: regulation and function

(2011) U. Forstermann et al.   EUROPEAN HEART JOURNAL

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Impact of high-throughput screening in biomedical research

(2011) Ricardo Macarron et al.   NATURE REVIEWS DRUG DISCOVERY

Diversity oriented synthesis: substitution at C5 in unreactive pyrimidines by Claisen rearrangement and reactivity in nucleophilic substitution at C2 and C4 in pteridines and pyrido[2,3-d]pyrimidines

(2011) Jonathan Adcock et al.   TETRAHEDRON

Pteridine–sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity

(2010) Sérgio M. Marques et al.   BIOORGANIC & MEDICINAL CHEMISTRY

4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

(2010) Kevin K.-C. Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis and in vitro evaluation of 2-amino-4-N-piperazinyl-6-(3,4-dimethoxyphenyl)-pteridines as dual immunosuppressive and anti-inflammatory agents

(2010) Steven De Jonghe et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer

(2010) M İlie et al.   BRITISH JOURNAL OF CANCER

TGF- -RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases

(2010) K. S. Mohammad et al.   CANCER RESEARCH

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

(2010) R.-D. Hofheinz et al.   CLINICAL CANCER RESEARCH

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)

(2010) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial

(2010) Martin Sebastian et al.   Journal of Thoracic Oncology

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

Bioequivalence evaluation of a triamterene–hydrochlorothiazide generic product: A new bioequivalence index for fixed-dose combinations

(2010) Mehrdad Hamidi et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Structures of dihydrofolate reductase-thymidylate synthase ofTrypanosoma cruziin the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate

(2009) Olga Senkovich et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Synthesis and Biological Activities of 2,4-Diaminopteridine Derivatives

(2009) Fei Ma et al.   ARCHIV DER PHARMAZIE

Control of catalysis in flavin-dependent monooxygenases

(2009) Bruce A. Palfey et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors

(2009) Louis H.A. Prins et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of 5-substituted 2-amino-4-chloro-8-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7,8-dihydropteridin-6(5H)-ones as potent and selective Hsp90 inhibitors

(2009) Xiaoyuan Li et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

(2009) A. G. Renner et al.   BLOOD

Neopterin, a prognostic marker in human malignancies

(2009) Robert Sucher et al.   CANCER LETTERS

Synthesis and biological evaluation of 2,4-diaminopteridine derivatives as nitric oxide synthase inhibitor

(2009) Fei Ma et al.   CHINESE CHEMICAL LETTERS

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

CRF Receptors as a Potential Target in the Development of Novel Pharmacotherapies for Depression

(2009) Glenn Valdez   CURRENT PHARMACEUTICAL DESIGN

Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase

(2009) Kirk E. Hevener et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the Leishmaniases

(2009) Lindsay B. Tulloch et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molybdenum cofactors, enzymes and pathways

(2009) Günter Schwarz et al.   NATURE

HIV-associated opportunistic pneumonias

(2009) Laurence HUANG et al.   RESPIROLOGY

Exploring 8-benzyl pteridine-6,7-diones as inhibitors of glutamate racemase (MurI) in Gram-positive bacteria

(2008) Gloria A. Breault et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System

(2008) Kelly J. Inglis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chloro-fac-tricarbonylrhenium(I) complexes of asymmetric azines derived from 6-acetyl-1,3,7-trimethylpteridine-2,4(1H,3H)-dione with hydrazine and aromatic aldehydes: Preparation, structural characterization and biological activity against several human tumor cell lines

(2008) I PICONFERRER et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Anticancer Photodynamic and Non-photodynamic Effects of Pterin Derivatives on a Pancreatic Cancer Cell Line

(2008) Takashi Miyoshi et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Aerosolized Phosphoinositide 3-Kinase  /  Inhibitor TG100-115 [3-[2,4-Diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a Therapeutic Candidate for Asthma and Chronic Obstructive Pulmonary Disease

(2008) J. Doukas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells

(2008) Alan Kambiz Fotoohi et al.   LEUKEMIA & LYMPHOMA

Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development

(2008) A. Cavazzuti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glutamate racemase as a target for drug discovery

(2008) Stewart L. Fisher   Microbial Biotechnology

Antitumor studies. Part 4: Design, synthesis, antitumor activity, and molecular docking study of novel 2-substituted 2-deoxoflavin-5-oxides, 2-deoxoalloxazine-5-oxides, and their 5-deaza analogs

(2007) Hamed I. Ali et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Evaluation of a series of bicyclic CXCR2 antagonists

(2007) Iain Walters et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS